Back to School: How biopharma can reboot drug development. Access exclusive analysis here
IMNX reported on a Phase I/II trial in pediatric patients receiving ICE (ifosfamide/carboplatin/etoposide) chemotherapy.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury